Phase 3 Readout
ZBIO: Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety
August 31, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 31, 2026
- Company
- Zenas BioPharma, Inc. (ZBIO)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety
- Company
- Zenas BioPharma, Inc. (ZBIO)
- Indication
- Warm Autoimmune Hemolytic Anemia